Detection of Specific Immune Cell Subpopulation Changes Associated with Systemic Immune Inflammation-Index Level in Germ Cell Tumors.
germ cell tumors
leukocyte subpopulations
lymphocytopenia
neutrophilia
systemic immune–inflammation index
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
02 May 2022
02 May 2022
Historique:
received:
01
04
2022
revised:
27
04
2022
accepted:
29
04
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
The tumor microenvironment (TME) and the host inflammatory response are closely interconnected. The interplay between systemic inflammation and the local immune response may influence tumor development and progression in various types of cancer. The systemic immune-inflammation index (SII) represents a prognostic marker for germ cell tumors (GCTs). The aim of the present study was to detect specific immune cell subpopulation changes which were associated with the SII level in chemotherapy-naïve GCT patients. In total, 51 GCT patients, prior to cisplatin-based chemotherapy, were included in the present study. Immunophenotyping of peripheral blood leukocyte subpopulations was performed using flow cytometry. The SII level was correlated with the percentage of various leukocyte subpopulations. The obtained results demonstrated that SII levels above the cut-off value of SII ≥ 1003 were associated with higher neutrophil percentages. An inverse correlation was found between the SII and the peripheral lymphocyte percentage that logically reflects the calculations of the SII index. Furthermore, the presented data also showed that in the lymphocyte subpopulation, the association with the SII was driven by T-cell subpopulations. In innate immunity-cell subpopulations, we observed a correlation between SII level and neutrophils as well as associations with eosinophil, basophil, natural killer cell and dendritic cell percentages. We suppose that the described interactions represent a manifestation of cancer-induced immune suppression. The results of the present study contribute to the elucidation of the interrelationship between tumor cells and the innate/adaptive immune system of the host.
Identifiants
pubmed: 35629346
pii: life12050678
doi: 10.3390/life12050678
pmc: PMC9147028
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Breast Cancer Res. 2006;8(1):R5
pubmed: 16417648
Breast Cancer Res. 2018 Nov 15;20(1):135
pubmed: 30442190
Cancer Cell. 2016 Aug 8;30(2):324-336
pubmed: 27424807
Clin Cancer Res. 2004 Nov 15;10(22):7466-74
pubmed: 15569976
Ann Oncol. 2016 Feb;27(2):294-9
pubmed: 26578732
Nat Med. 2011 Jun;17(6):700-7
pubmed: 21552268
Oncoimmunology. 2017 Nov 13;7(2):e1393134
pubmed: 29308325
Lancet. 2000 Nov 25;356(9244):1795-9
pubmed: 11117911
J Transl Med. 2019 Jan 18;17(1):30
pubmed: 30658662
Int J Urol. 2019 Jan;26(1):31-47
pubmed: 30253448
Cancer Res. 2016 Apr 15;76(8):2153-65
pubmed: 27197252
Hum Vaccin Immunother. 2014;10(11):3224-35
pubmed: 25483675
Elife. 2020 Jan 14;9:
pubmed: 31931959
Cancer Epidemiol. 2013 Aug;37(4):492-7
pubmed: 23623488
Immunity. 2008 Apr;28(4):571-80
pubmed: 18394936
Nat Rev Cancer. 2011 Feb;11(2):123-34
pubmed: 21258396
Oncoimmunology. 2019 Apr 13;8(7):1593803
pubmed: 31143512
Target Oncol. 2020 Dec;15(6):773-785
pubmed: 33044683
Front Immunol. 2020 May 21;11:924
pubmed: 32508825
Nat Immunol. 2015 Jun;16(6):609-17
pubmed: 25915731
Br J Cancer. 2018 Mar 20;118(6):831-838
pubmed: 29485980
Oncoimmunology. 2017 Mar 20;6(4):e1305535
pubmed: 28507813
Clin Transl Oncol. 2019 Jul;21(7):836-844
pubmed: 30470994
Onco Targets Ther. 2015 Jun 08;8:1355-62
pubmed: 26089685
Cancer Res. 2009 Jul 1;69(13):5383-91
pubmed: 19549917
Int Urol Nephrol. 2019 Dec;51(12):2189-2199
pubmed: 31456101
J Cell Physiol. 2019 Jun;234(6):8509-8521
pubmed: 30520029
Cells. 2020 Jul 07;9(7):
pubmed: 32645919
Oncotarget. 2016 Sep 27;7(39):63204-63214
pubmed: 27556503
Biomark Med. 2019 Dec;13(18):1565-1575
pubmed: 31631675
Ann Surg Oncol. 2020 Mar;27(3):898-906
pubmed: 31792715
Clin Cancer Res. 2014 Dec 1;20(23):6212-22
pubmed: 25271081
Br J Haematol. 2018 Jun;181(6):837-840
pubmed: 28439879
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Cancer Med. 2018 Mar;7(3):690-697
pubmed: 29468834
Asia Pac J Clin Oncol. 2018 Oct;14(5):e243-e251
pubmed: 29532611
Lancet Oncol. 2013 May;14(6):e218-28
pubmed: 23639322
Cancer Res. 2016 Apr 1;76(7):1792-803
pubmed: 26873846
Lung. 2020 Apr;198(2):405-414
pubmed: 32016563
Br J Cancer. 2021 Jan;124(2):359-367
pubmed: 32929195
J Cell Physiol. 2019 Aug;234(10):18408-18414
pubmed: 30891768
J Hematol Oncol. 2021 Jan 6;14(1):7
pubmed: 33407739
Cancer. 1983 Jul 1;52(1):126-30
pubmed: 6850535
Cancers (Basel). 2021 Apr 07;13(8):
pubmed: 33916925
Future Oncol. 2019 Oct;15(29):3367-3379
pubmed: 31424272
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
Cancer Cell. 2014 Nov 10;26(5):638-52
pubmed: 25446897
Gastric Cancer. 2020 Jan;23(1):73-81
pubmed: 31267360
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Cancer Manag Res. 2019 May 02;11:3973-3979
pubmed: 31118810
Cancer Res. 2017 Jan 15;77(2):291-302
pubmed: 27879269
Front Immunol. 2020 Jan 21;10:3038
pubmed: 32038612
Sci Rep. 2017 May 4;7(1):1494
pubmed: 28473700
Front Immunol. 2020 Sep 30;11:583304
pubmed: 33101311
J Immunol. 2010 Jul 15;185(2):795-802
pubmed: 20601611
Front Oncol. 2020 Aug 14;10:1325
pubmed: 32923384
Int J Cancer. 2020 Feb 1;146(3):692-698
pubmed: 30924141
Immunity. 2019 Jul 16;51(1):27-41
pubmed: 31315034
Br J Cancer. 2018 Mar 20;118(6):825-830
pubmed: 29485982
Cell Mol Immunol. 2019 May;16(5):415-422
pubmed: 30911118
Sci Rep. 2019 Mar 1;9(1):3284
pubmed: 30824727
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
J Clin Invest. 2013 Jul 1;:
pubmed: 23863628
J Cancer. 2019 Jun 2;10(14):3188-3196
pubmed: 31289589
Leuk Res. 2007 Jul;31(7):915-20
pubmed: 17123603
Cancer Cell. 2017 Aug 14;32(2):135-154
pubmed: 28810142
Nat Rev Immunol. 2002 Jan;2(1):46-53
pubmed: 11905837
Immunity. 2016 Apr 19;44(4):924-38
pubmed: 27096321
Gynecol Oncol. 2019 Feb;152(2):259-264
pubmed: 30558974
PLoS One. 2014 Oct 01;9(10):e109018
pubmed: 25272036
BMC Cancer. 2018 Dec 3;18(1):1202
pubmed: 30509242
Cancer Discov. 2016 Jan;6(1):71-9
pubmed: 26493961
Cancer Res. 1999 Mar 15;59(6):1295-300
pubmed: 10096562
Cancer Cell Int. 2020 Jun 09;20:224
pubmed: 32528232
Cancer Res. 2009 Apr 15;69(8):3563-9
pubmed: 19351841
Clin Transl Med. 2020 Feb 10;9(1):6
pubmed: 32037496
Immunity. 2019 May 21;50(5):1317-1334.e10
pubmed: 30979687
Oncoimmunology. 2015 Aug 31;5(2):e1082028
pubmed: 27057464
Blood. 2013 Nov 21;122(22):3666-77
pubmed: 24113869
J Thorac Oncol. 2018 Jan;13(1):97-105
pubmed: 29170120
Front Physiol. 2018 Mar 07;9:167
pubmed: 29563880
J Immunother Cancer. 2018 Oct 17;6(1):107
pubmed: 30333065
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
Clin Transl Oncol. 2020 Jan;22(1):81-90
pubmed: 31004253